Wealth Enhancement Advisory Services LLC Boosts Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in IQVIA Holdings Inc. by 53.0% during Q2, owning 20,289 shares valued at $3.33 million.
• Multiple institutional investors have recently boosted their positions in IQVIA, with 89.62% of the stock now owned by such entities.
• IQVIA reported Q2 earnings of $2.81 per share, exceeding analysts' expectations, with a revenue increase of 5.3% year-over-year to $4.02 billion.

Wealth Enhancement Advisory Services LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 53.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,289 shares of the medical research company's stock after purchasing an additional 7,030 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in IQVIA were worth $3,332,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in IQV. Brighton Jones LLC lifted its position in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after acquiring an additional 2,537 shares during the period. Wellington Management Group LLP raised its stake in shares of IQVIA by 12.7% during the fourth quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company's stock worth $1,924,000 after purchasing an additional 1,106 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 129.5% during the first quarter. Versant Capital Management Inc now owns 677 shares of the medical research company's stock worth $119,000 after purchasing an additional 382 shares during the period. GAMMA Investing LLC grew its position in IQVIA by 27,448.4% in the 1st quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company's stock valued at $68,286,000 after buying an additional 385,925 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its position in IQVIA by 12.6% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,070 shares of the medical research company's stock worth $365,000 after buying an additional 231 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE:IQV opened at $179.51 on Friday. The company has a market cap of $30.52 billion, a P/E ratio of 25.98, a P/E/G ratio of 1.94 and a beta of 1.32. The business has a fifty day simple moving average of $187.01 and a 200-day simple moving average of $167.28. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm posted $2.64 earnings per share. IQVIA's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently commented on IQV. Truist Financial raised their price target on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Mizuho boosted their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Jefferies Financial Group upgraded shares of IQVIA from a "hold" rating to a "buy" rating and raised their price objective for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. UBS Group upped their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. Eighteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.